Full Press Release Details
Announces Investor and Media Outreach Programs
Calif. and VANCOUVER, British Columbia, April 15, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT)
("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies
for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance
communication with investors and increase investor awareness of and interest in the Company, its product candidates, and its clinical
programs. The comprehensive program is expected to enhance BriaCell's dialogue with institutional and retail investors,
industry analysts, and the investing public. The following IR and PR groups are currently engaged by the Company. It is important
to disclose that BriaCell is unrelated and unaffiliated with each of the following entities, but the following firms and their
clients may have an interest, directly or indirectly, in the securities of BriaCell.
LLC d/b/a CORE IR ("Core IR"): Based in Garden City, NY, Core IR is a leading investor relations firm that provides
investor relations services pursuant to a marketing and consulting agreement dated March 15, 2021 and amended on April 9, 2021
(the " Agreement"). Services will include the initiation of strategic market and investor awareness programs
by providing comprehensive corporate and shareholder communications development services that will promote the Company's
brand. All such services and goals are subject to the prior approval of the Company. The Agreement has a six-month term ("Initial
Term") and thereafter automatically renews for consecutive six-month terms ("Renewal Term"), unless
BriaCell or Core IR provide written notice of its intention not to renew the Agreement five (5) days prior to the end of the Initial
Term or any Renewal Term. Core IR will be compensated out of working capital in monthly instalments of USD$13,500 ("Monthly
Retainer"). In addition to the Monthly Retainer, BriaCell has granted Core IR an option to purchase up to 60,000 common
shares of BriaCell ("Options") under BriaCell's stock option plan dated November 24, 2014. The Options
are exercisable at US$4.24 per common share of BriaCell ("Shares"). The right to exercise the Options vests
in four quarterly installments of 15,000 Shares while the contract is in effect, with the first installment to vest on July 12,
2021. BriaCell has no interest in Core IR or its securities. Core IR has no interest in BriaCell or its securities, except as
set out in this news release. Core IR is not a Non-Arm's Length Party of BriaCell, as that term is defined in TSX Venture
Exchange ("TSXV") policies. The engagement of CORE IR remains subject to the approval of the TSXV.
Media Inc. d/b/a Investing News Network ("INN"): INN is a private company headquartered in Vancouver, Canada,
dedicated to providing independent news and education to investors since 2007. BriaCell entered into a campaign allocation agreement
with INN on March 29, 2021 for a term of 12-months (the "INN Agreement"). Pursuant to the INN Agreement, INN
will provide advertising to increase awareness of the Company. INN does not provide Investor Relations or Market Making services.
The INN Agreement is a non-cancellable binding contract. INN will be compensated out of working capital semi-annually in the amount
of US$68,000. INN currently holds 1,163 shares of Briacell. INN is not a Non-Arm's Length Party of BriaCell, as that term
is defined in TSX Venture Exchange policies. The engagement of INN remains subject to the approval of the TSXV.
Inc.: Based in Cedar Park, TX, SmallCapVoice.com, Inc. ("SmallCapVoice"), is a leading online marketing
and investor relations firm that specializes in providing investor communication services to small cap companies using online
tools like Search engine optimization (SEO), social media, email campaigns, audio interviews, etc. It is known for its
ability to help emerging growth companies build a following among retail and institutional investors in the United States and
Canada. On March 24, 2020, BriaCell entered into a financial public relations agreement with SmallCapVoice for a term of one month
("SmallCapVoice Agreement"). Services provided to the Company under the SmallCapVoice Agreement include social
media, email campaigns, and audio interviews. SmallCapVoice shall be compensated out of working capital at the end of each month
in the amount of US$3,250. Either party to the SmallCapVoice Agreement may terminate the SmallCapVoice Agreement upon one month
notice to the other party. The engagement of SmallCapVoice remains subject to the approval of the TSXV.
to the option issuance disclosed on March 30, 2021, the options will have an amended effective date of April 13, 2021. All other
terms and quantities remain the same.
BriaCell Therapeutics Corp.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
additional information on BriaCell, please visit: https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "aim," "should," "will" "would," or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements
are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult
to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be
accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in
the Company's SEC filings. Forward-looking statements contained in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
William V. Williams, MD
Director of Public Relations